Unsere Publikationen

Ziemssen T, Centonze D. Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing. Mult Scler. 2025 Jun;31(7):751-753. doi: 10.1177/13524585251346658. Epub 2025 Jun 14. PMID: 40515640.

Link
https://doi.org/10.1177/13524585251346658
Tags
Multiple SkleroseMS Behandlung
Jahr
2025
Autoren
Ziemssen T, Centonze D.
Verlag
Mult Scler. 2025 Jun;31(7):751-753.
Zum Eintrag

CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany

Link
https://doi.org/10.3389/fneur.2025.1564327
Tags
Multiple SkleroseMS Behandlung
Jahr
2025
Autoren
Buttmann M, Weber MS, Meuth SG, Blümich S, Hieke-Schulz S, Dirks P, Eggebrecht JC, Ziemssen T.
Verlag
Front Neurol. 2025 May 21;16:1564327.
Zum Eintrag

RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis

Link
https://doi.org/10.3389/fneur.2025.1557947
Tags
Multiple SkleroseMS BehandlungManagement & ScienceeHealth
Jahr
2025
Autoren
Praet J, Anderhalten L, Comi G, Horakova D, Ziemssen T, Vermersch P, Lukas C, Van Leemput K, Steppe M, Manero N, Kadas E, Bernard A, van Rampelbergh J, de Boer E, Zingler V, Smeets D, Ribbens A, Paul F.
Verlag
Front Neurol. 2025 May 16;16:1557947.
Zum Eintrag

Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis

Link
https://doi.org/10.1056/nejmoa2415988
Tags
Multiple SkleroseMS Behandlung
Jahr
2025
Autoren
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Ziemssen T, Reich DS; HERCULES Trial Group.
Verlag
N Engl J Med. 2025 May 15;392(19):1883-1892.
Zum Eintrag

Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs

Link
https://doi.org/10.3390/pathogens14030235
Tags
Multiple Sklerose
Jahr
2025
Autoren
Solchenberger H, Odendahl M, Schriefer D, Proschmann U, Rahbani GKa, Ziemssen T, Akgün K.
Verlag
Pathogens. 2025; 14(3):235.
Zum Eintrag

Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study

Link
https://doi.org/10.1177/17562864241306575
Tags
Multiple SkleroseMS Behandlung
Jahr
2025
Autoren
Ziemssen T, Bass AD, Van Wijmeersch B, Eichau S, Richter S, Hoffmann F, Armstrong NM, Chirieac M, Cunha-Santos J, Singer BA.
Verlag
Ther Adv Neurol Disord. 2025 Feb 10;18:17562864241306575.
Zum Eintrag

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS

Link
https://doi.org/10.1212/WNL.0000000000210142
Tags
Multiple SkleroseMS Behandlung
Jahr
2025
Autoren
Cerqueira JJ, Berthele A, Cree BAC, Filippi M, Pardo G, Pearson OR, Traboulsee A, Ziemssen T, Vollmer T, Bernasconi C, Mandel CR, Kulyk I, Chognot C, Raposo C, Schneble HM, Thanei GA, Incera E, Havrdová EK.
Verlag
Neurology. 2025 Feb 25;104(4):e210142.
Zum Eintrag

A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?

Link
https://doi.org/10.1080/17582024.2024.2441068
Tags
Multiple SkleroseMS Behandlung
Jahr
2025
Autoren
Barrett Amy, Olayinka-Amao O, Ziemssen T, Bharadia T, Henke C, Kamudoni P.
Verlag
Neurodegenerative Disease Management, January, 1–8.
Zum Eintrag

Publikationen durchsuchen

Publikationen filtern

Filter
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Zeige alleVerstecke
Jahr
-